NASDAQ:SCTL - Nasdaq - US75629F1093 - Common Stock - Currency: USD
1.1
+0.01 (+0.92%)
The current stock price of SCTL is 1.1 USD. In the past month the price increased by 3.77%. In the past year, price increased by 2.8%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY | ELI LILLY & CO | 67.21 | 829.40B | ||
NVO | NOVO-NORDISK A/S-SPONS ADR | 27.44 | 390.99B | ||
JNJ | JOHNSON & JOHNSON | 16.25 | 390.76B | ||
AZN | ASTRAZENECA PLC-SPONS ADR | 20.56 | 230.17B | ||
MRK | MERCK & CO. INC. | 11.71 | 226.40B | ||
NVS | NOVARTIS AG-SPONSORED ADR | 13.77 | 215.98B | ||
PFE | PFIZER INC | 8.46 | 149.04B | ||
SNY | SANOFI-ADR | 13.58 | 136.54B | ||
BMY | BRISTOL-MYERS SQUIBB CO | 48.97 | 113.23B | ||
GSK | GSK PLC-SPON ADR | 7.78 | 74.77B | ||
ZTS | ZOETIS INC | 27.1 | 72.39B | ||
TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.95 | 44.58B |
Societal CDMO, Inc. is a bi-coastal CDMO with capabilities spanning pre-investigational new drug (IND) development to commercial manufacturing and packaging for a range of therapeutic dosage forms with a focus on small molecules. The company is headquartered in Exton, Pennsylvania and currently employs 275 full-time employees. The company went IPO on 2014-03-07. The firm is engaged in spanning pre-investigational new drug development to commercial manufacturing and packaging for a range of therapeutic dosage forms with a primary focus on the area of small molecules. The company is involved in CDMO providing therapeutic development, end-to-end regulatory support, clinical and commercial manufacturing, aseptic fill/finish, lyophilization, packaging and logistics services to the global pharmaceutical market. The Company’s products include Ritalin LA, Focalin XR, Verelan PM, Verelan SR, Verapamil PM, Verapamil SR, Donnatal liquids and tablets and Scot-Tussin cough and cold liquids. Its manufacturing and development capabilities include product development from formulation through clinical trial and commercial manufacturing, and specialized capabilities for solid oral dosage forms and facilities to handle highly potent compounds and controlled substances.
SOCIETAL CDMO INC
1 E. Uwchlan Ave, Suite 112
Exton PENNSYLVANIA US
Employees: 275
Company Website: https://www.societalcdmo.com/
Phone: 17705348239
The current stock price of SCTL is 1.1 USD. The price increased by 0.92% in the last trading session.
The exchange symbol of SOCIETAL CDMO INC is SCTL and it is listed on the Nasdaq exchange.
SCTL stock is listed on the Nasdaq exchange.
10 analysts have analysed SCTL and the average price target is 1.12 USD. This implies a price increase of 2% is expected in the next year compared to the current price of 1.1. Check the SOCIETAL CDMO INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
SOCIETAL CDMO INC (SCTL) has a market capitalization of 116.26M USD. This makes SCTL a Micro Cap stock.
SOCIETAL CDMO INC (SCTL) currently has 275 employees.
SOCIETAL CDMO INC (SCTL) has a support level at 1.07 and a resistance level at 1.1. Check the full technical report for a detailed analysis of SCTL support and resistance levels.
The Revenue of SOCIETAL CDMO INC (SCTL) is expected to grow by 2.59% in the next year. Check the estimates tab for more information on the SCTL EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
SCTL does not pay a dividend.
SOCIETAL CDMO INC (SCTL) will report earnings on 2024-05-08, after the market close.
SOCIETAL CDMO INC (SCTL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.16).
ChartMill assigns a technical rating of 9 / 10 to SCTL. When comparing the yearly performance of all stocks, SCTL is one of the better performing stocks in the market, outperforming 98.08% of all stocks.
ChartMill assigns a fundamental rating of 2 / 10 to SCTL. SCTL may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months SCTL reported a non-GAAP Earnings per Share(EPS) of -0.16. The EPS increased by 40.74% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -8.64% | ||
ROE | -22.61% | ||
Debt/Equity | 0.01 |
ChartMill assigns a Buy % Consensus number of 78% to SCTL. The Buy consensus is the average rating of analysts ratings from 10 analysts.
For the next year, analysts expect an EPS growth of 45.81% and a revenue growth 2.59% for SCTL